← Leaderboards
Andrew Gardiner
Libero Pharma Limited
$6,351,015
Attributed
$6,351,015
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $3.2M · FY2022–23$5M$3.8M$2.5M$1.3M$0
'22
'23
Funding mix
By agency
NIH$6,351,015 · 1
By mechanism
UG3$6,351,015 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Efficacy Evaluation”
- Angee Greer · Ppd Development Lp$82,531,927
- Christina Millin · Rho Federal Systems Division, Inc.$31,828,916
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Suma Babu · Massachusetts General Hospital$26,348,733
- Kevin Saunders · Duke University$18,106,404
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
Efficacy EvaluationEuropean UnionAdherenceDrug StabilityAgonistAddictionAlternative TreatmentBenefit SharingAntagonistCaviaChronicClinical DevelopmentClinical ResearchAuthorization DocumentationBehavioralCostCost EffectiveCravingCyclic GmpCaringDouble-Blind MethodDrug DevelopmentDrug KineticsExercise